Thrombotic Microangiopathies ( TM ),Thrombotic Thrombocytopenic Purpura ( TTP ) - Hematology скачать в хорошем качестве

Thrombotic Microangiopathies ( TM ),Thrombotic Thrombocytopenic Purpura ( TTP ) - Hematology

📌 𝐅𝐨𝐥𝐥𝐨𝐰 𝐨𝐧 𝐈𝐧𝐬𝐭𝐚𝐠𝐫𝐚𝐦:-   / drgbhanuprakash   📌𝗝𝗼𝗶𝗻 𝗢𝘂𝗿 𝗧𝗲𝗹𝗲𝗴𝗿𝗮𝗺 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 𝗛𝗲𝗿𝗲:- https://t.me/bhanuprakashdr 📌𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝗧𝗼 𝗠𝘆 𝗠𝗮𝗶𝗹𝗶𝗻𝗴 𝗟𝗶𝘀𝘁:- https://linktr.ee/DrGBhanuprakash Thrombotic Microangiopathies ( TM ) ,Thrombotic Thrombocytopenic Purpura ( TTP ) - --------------------------------------------------------------------------------------------------------------- Thrombotic Microangiopathies (TM) are a group of severe, life-threatening conditions characterized by widespread microvascular thrombosis leading to organ damage. They include Thrombotic Thrombocytopenic Purpura (TTP), Hemolytic Uremic Syndrome (HUS), and Atypical HUS. The hallmark of TM is the formation of microthrombi in small blood vessels due to endothelial injury, which leads to **microangiopathic hemolytic anemia (MAHA) 🩸 (fragmentation of red blood cells), thrombocytopenia (low platelet count), and organ ischemia. Common organs affected include the kidneys, brain, and heart. In TTP, the primary problem is a severe deficiency of the enzyme ADAMTS13, which normally cleaves von Willebrand factor (vWF) into smaller units. Without ADAMTS13, large vWF multimers cause excessive platelet aggregation and clot formation in the microvasculature, leading to the characteristic clinical pentad: thrombocytopenia, MAHA, neurologic symptoms (e.g., confusion, seizures), renal dysfunction, and fever. Diagnosis involves blood tests showing fragmented red cells (schistocytes) 🧬 on a peripheral smear, elevated lactate dehydrogenase (LDH), and reduced haptoglobin. The diagnosis of TTP is confirmed with an ADAMTS13 activity assay , which reveals severely reduced enzyme activity (usually less than 10%). Treatment for TTP is urgent and includes plasma exchange therapy 🏥, which removes large vWF multimers and replenishes ADAMTS13. Additional treatments include corticosteroids and rituximab to reduce the autoimmune attack on ADAMTS13. The introduction of **Caplacizumab**, a nanobody that inhibits the interaction between vWF and platelets, has improved outcomes by preventing further clot formation. Rapid diagnosis and treatment are crucial in TTP, as delays can lead to severe complications like stroke, renal failure, and multiorgan dysfunction. #ThromboticMicroangiopathies #TTP #HemolyticUremicSyndrome #HUS #BloodDisorders #MicroangiopathicHemolyticAnemia #ADAMTS13 #PlasmaExchange #Hematology #MedicalEducation #NEETPG #USMLE #FMGE #Thrombocytopenia #Rituximab #Caplacizumab #HematologicEmergencies #ThromboticThrombocytopenicPurpura #TTP #BloodDisorders #ADAMTS13 #PlasmaExchange #Rituximab #Hematology #MedicalEducation #NEETPG #USMLE #FMGE #RareDiseases #Thrombocytopenia #medicalanimations #fmge #fmgevideos #rapidrevisionfmge #fmge2024 #mbbslectures #nationalexitexam #nationalexittest #neetpg #usmlepreparation #usmlestep1 #fmge #usmle #drgbhanuprakash #medicalstudents #medicalstudent #medicalcollege #neetpg2025 #usmleprep #usmlevideos #usmlestep1videos #medicalstudents #neetpgvideos #usmlestep2videos